***Template v1 dated October 2023***

**Project Portfolio**

**Project Name**

**Company Name, City**

*(Please name the legal entity, including the legal identification number.)*

Member State

Company logo

**Project period:**

MM.YYYY – MM.YYYY

*Target maximum length of the document: 50-75 pages plus annexes*

Table of Contents

[How to fill in the project portfolio (PP): 4](#_Toc181973156)

[1 Introduction 6](#_Toc181973157)

[1.1 Company presentation 6](#_Toc181973158)

[1.2 Additional information on the company and the aid to be presented by the Member State 6](#_Toc181973159)

[1.3 Executive summary of the project 7](#_Toc181973160)

[2 Contribution of the individual project to EU objectives and strategies 7](#_Toc181973161)

[3 Research, Development, Innovation and First Industrial Deployment (points 22-24 of the IPCEI Communication) 7](#_Toc181973162)

[3.1 R&D&I Projects before IPCEI (for developing the IPCEI-project’s outcome at earlier research stages) 8](#_Toc181973163)

[3.2 R&D&I and FID activities in the IPCEI project 8](#_Toc181973164)

[3.2.1 Overview of the project 8](#_Toc181973165)

[3.2.1.1 Final outcome and objectives of the project 8](#_Toc181973166)

[3.2.1.2 R&D&I and FID, objectives, challenges and approach to overcome challenges 9](#_Toc181973167)

[3.2.1.3 Structure of the project 9](#_Toc181973168)

[3.2.2 GSOA that concerns your project 9](#_Toc181973169)

[3.2.3 R&D&I part of the project 9](#_Toc181973170)

[3.2.3.1 R&D&I activities of the project 9](#_Toc181973171)

[3.2.3.2 Major innovative nature of the project 9](#_Toc181973172)

[3.2.4 FID part of the project 10](#_Toc181973173)

[3.2.4.1 FID activities 10](#_Toc181973174)

[3.2.4.2 Compliance of the FID activities with the IPCEI Communication criteria 10](#_Toc181973175)

[3.2.4.3 Duration of FID and KPI 11](#_Toc181973176)

[3.2.4.4 Sales during FID 11](#_Toc181973177)

[3.3 GANTT chart 12](#_Toc181973178)

[4 Necessity (incl. incentive effect) and proportionality of the aid 12](#_Toc181973179)

[4.1 Incentive effect 12](#_Toc181973180)

[4.2 Necessity of the aid 12](#_Toc181973181)

[4.3 Appropriateness of the aid instrument 13](#_Toc181973182)

[4.4 Proportionality of the State aid 13](#_Toc181973183)

[4.4.1 Requested amount of State aid 14](#_Toc181973184)

[4.4.2 Costs of the project 14](#_Toc181973185)

[4.4.2.1 Costs of feasibility studies and of obtaining required permissions 14](#_Toc181973186)

[4.4.2.2 Costs of instruments and equipment 15](#_Toc181973187)

[4.4.2.3 Costs of the acquisition or construction of buildings, infrastructure and land 16](#_Toc181973188)

[4.4.2.4 Costs of other materials, supplies and similar products necessary for the project 16](#_Toc181973189)

[4.4.2.5 Costs of patents and contractual research 17](#_Toc181973190)

[4.4.2.6 Personnel and administrative costs (including overheads) 18](#_Toc181973191)

[4.4.2.7 Other costs 18](#_Toc181973192)

[4.4.3 Eligible costs 18](#_Toc181973193)

[4.4.3.1 Eligible costs for R&D&I and FID project 18](#_Toc181973194)

[4.4.4 Duration of mass production phase or operational phase 21](#_Toc181973195)

[4.4.5 Revenues and cost savings in mass production phase or operational phase 21](#_Toc181973196)

[4.4.6 Aid beneficiary’s weighted average cost of capital (WACC) 21](#_Toc181973197)

[4.4.7 Terminal Value (TV) 22](#_Toc181973198)

[4.4.8 Taxes 22](#_Toc181973199)

[4.5 Other public funding (including EU funding) and State aid cumulation 23](#_Toc181973200)

[4.6 Claw-back mechanism 23](#_Toc181973201)

[4.7 Co-financing 23](#_Toc181973202)

[5 Integration of the project in the IPCEI 23](#_Toc181973203)

[5.1 Insertion in a common structure, programme, roadmap 24](#_Toc181973204)

[5.2 Contribution of the individual project to the integrated IPCEI 24](#_Toc181973205)

[5.2.1 Significant added value of the project 24](#_Toc181973206)

[5.2.2 Complementarity of the project 24](#_Toc181973207)

[5.3 Collaborations with IPCEI Direct Participants 25](#_Toc181973208)

[6 Market failures affecting the individual project 27](#_Toc181973209)

[6.1 Negative externalities 27](#_Toc181973210)

[6.2 Positive externalities 28](#_Toc181973211)

[6.3 Coordination failures 28](#_Toc181973212)

[6.4 Asymmetric information 29](#_Toc181973213)

[6.5 Other market failures 29](#_Toc181973214)

[7 Spillover effects 29](#_Toc181973215)

[7.1 Spillover effects by wide dissemination of non-IP protected knowledge and results acquired in your project 30](#_Toc181973216)

[7.2 Spillover effects for IP-protected knowledge and results 31](#_Toc181973217)

[7.3 Specific spillover effects in FID phase 32](#_Toc181973218)

[7.4 Spillover effects through collaboration with indirect and associated partners 32](#_Toc181973219)

[7.5 Other spillover effects 33](#_Toc181973220)

[7.6 Overview of spillover effects 33](#_Toc181973221)

[8 Compliance with the ‘Do no significant harm’ principle 34](#_Toc181973222)

[9 Limitation of undue distortions of competition and trade 34](#_Toc181973223)

[9.1 Markets affected 34](#_Toc181973224)

[9.2 Limiting the negative effects on competition 36](#_Toc181973225)

[9.2.1 Limiting the risk of overcapacity 36](#_Toc181973226)

[9.2.2 Limiting the risk of foreclosure and distortion of dynamic incentives 36](#_Toc181973227)

[9.2.3 Limiting the risk of dominance 36](#_Toc181973228)

[9.2.4 Not creating or maintaining an inefficient market structure 36](#_Toc181973229)

[9.2.5 No effect on location activities 37](#_Toc181973230)

[10 Reporting 37](#_Toc181973231)

[11 Annexes to the project portfolio 37](#_Toc181973232)

# How to fill in the project portfolio (PP):

*Disclaimer: This template is a working document. It does neither represent an official position of the Commission nor a formally approved interpretation of the IPCEI Communication. It is based on the experience gained by the Services of DG COMP in the assessment of IPCEI projects and is provided to facilitate the (pre-)notification and assessment process of IPCEI. This working document may be subject to revision.*

1. ***General instructions***
   1. ***Please do not change the structure of this template****. The information requested herein is essential for the assessment of your IPCEI project. Should you believe that additional type of information is equally essential for the assessment of your project, please insert it in a new section at the end of the PP and use annexes if necessary.*
   2. *When preparing your PP, please* ***delete all instructions and explanations*** *provided in this template with a view to guide your company through the process of compiling the information necessary to demonstrate your project’s compliance with the requirements of the* [*IPCEI Communication*](https://eur-lex.europa.eu/legal-content/EN/TXT/HTML/?uri=PI_COM:C(2021)8481)*.*
   3. *Please* ***use the actual names of the structural elements of the IPCEI*** *you are participating in. If they are further structured (for instance in Work packages (WP) or tasks, etc.), provide the information as requested also at the level of these further sub-structures.*
2. **Who has to prepare the PP?**
   1. *The PP has to be prepared by the companies benefitting from aid under responsibility of the notifying Member State. The beneficiaries, whose projects will be (pre-) notified, are referred to as ‘IPCEI* ***direct participants****’. Other participants in an IPCEI ecosystem, for whom the Member State does NOT ask for approval of aid under the IPCEI communication, do not need to present a PP to the Commission. These may concern company projects that have been participating in the IPCEI calls but are benefitting from aid based on other legal bases (in particular, the General Block Exemption Regulation - GBER), or do not receive State aid at all (such as, in some circumstances, research organisations/universities), thus not assessed by the Commission. They are part of an IPCEI-created ecosystem through collaborations with other IPCEI participants, thereby contributing to the relevant policy objectives pursued by the proposed IPCEI.[[1]](#footnote-2) They have been labelled as ‘indirect’ or ‘associated’ partners or participants in previous decisions; this template uses the term ‘indirect partners’ for simplicity reasons.*
   2. *Each legal entity, regardless of it being part of the same company, which might even be a group, should submit a separate PP, funding gap (FG) and competition assessment templates,* ***if*** *State aid for* ***separate projects*** *is envisaged and (pre-) notified. This is often the case for legal entities of one group in different Member States.*
3. ***What is the ‘project’ to be described in the PP?***

*The Direct participants should in principle present separate PP (together with separate FG and competition assessment templates) for each* ***project*** *it submits for direct participation in the IPCEI (implying state funding).*

*For the purpose of this PP, a ‘****project****’ encompasses activities spanning over one or several categories of research and development and innovation (R&D&I) and first industrial deployment (FID), which are intended to accomplish an indivisible task of a precise nature with clearly pre-defined goals. A project may consist of several WP or sub-projects, activities or services, and must include clear objectives, activities to be carried out to achieve those objectives (including their expected costs), and concrete deliverables to identify the outcomes of those activities and compare them with the relevant objectives. Conversely, when two or more projects by the same company aim at achieving distinct, divisible outcomes that lead to separate revenue streams, they should in principle form distinct projects and be separated in two PP and FG.*

1. ***Length of the PP***

*Please endeavour to limit the PP to an indicative* ***50-75 pages maximum****, focusing on your concrete project and its substance. Do not copy texts from the Chapeau of the IPCEI or annexes to it, neither provide general information (for instance: general theoretical descriptions of types of research or general high level market information). Should you attach annexes to it, the relevant section of the PP should contain the argument made in the respective annex and an executive summary of the information provided. Please* ***avoid*** *repetitions and general or marketing type of statements.*

1. Introduction
   1. Company presentation
2. *A general description of your company:*

*Please give a description of the legal entity that is expected to be the beneficiary of the State aid including: full name, abbreviation to be used, seat and legal identification number, whether it is part of a group, whether it is a Joint-Venture (if so, when it was created and who are the founders) and what are the main activities of the entity. Avoid general marketing and PR type of statements and provide only a factual presentation. Please, explicitly indicate if another entity from the same group is expected to participate in the same IPCEI with another project.*

1. *Size of the company:*

*Please indicate whether your company qualifies as small, medium or large enterprise within the meaning of Annex I to the General Block Exemption Regulation[[2]](#footnote-3)(GBER). Please also provide the supporting information (number of employees and annual revenues to demonstrate SME status). In case your company qualifies as a SME, please annex to the PP the necessary evidence to justify your declaration.*

1. *Company in difficulty:*

*Please confirm that you are* ***not*** *a company in difficulty as defined in Article 2 (18) of the GBER[[3]](#footnote-4) and point 20 of Rescue and Restructuring Guidelines[[4]](#footnote-5).*

1. *Summary description of your company*
   1. Additional information on the company and the aid to be presented by the Member State

*Please verify with your State aid and other relevant national authorities the absence of factors which would render your project ineligible for State aid under the IPCEI Communication, in particular that:*

* + *you are* ***not*** *subject to an outstanding recovery order following a previous Commission decision declaring aid illegal and incompatible with the internal market;*
  + *the aid does* ***not*** *constitute a non-severable violation of Union law;*
  + *the aid is* ***not subject*** *to the obligation for your company to have its headquarters in the Member State concerned or be predominantly established in that Member State;*
  + *the aid is* ***not subject*** *to the obligation for your company to use nationally produced goods or national services;*
  + *the aid does* ***not*** *restrict the possibility for your company to use the obtained R&D&I in other Member States.*
  1. Executive summary of the project

*Please summarize in non-confidential and non-technical terms your project; be as concrete as possible and avoid marketing and PR language. Please include the following information:*

* *Description of the project: what is it about and what are the expected outcomes (i.e., products, processes, services etc.).*
* *Short description of the expected innovations going beyond the global state-of-the-art (GSOA) (i.e., summarize the planned R&D&I activities)*
* *Short description of the planned FID activities and in particular how the FID part is significantly based on R&D&I and how therefore would result in a new product or (production/ service) process with high innovation content going beyond GSOA*
* *What/who will be the use/users of the planned outcome and main customers*
* *Duration of the project*
* *Location(s) of the project (municipality, region, state)*
* *How your project concretely and uniquely contributes to this IPCEI (how does it concretely add significant value to the IPCEI as a whole) and how it complements the other projects*
* *List your main cross-border collaboration partners within this IPCEI and summarize the collaborations with them, demonstrating your project’s integration within the IPCEI*
* *Target Size: 50 lines*
* *A graphic representation of your project, incl. main supplier/provider of input and main customers/consumers of output*

1. Contribution of the individual project to EU objectives and strategies

*In this section, please describe* ***briefly******in concrete and specific terms******how******your project*** *itself contributes to the EU objectives and strategies[[5]](#footnote-6) described in the Chapeau document that the IPCEI to which you are taking part into claims to be contributing.*

***Do not*** *copy here any text from the Chapeau that is relevant to the overall IPCEI. However, describe your* ***specific*** *contribution (of your* ***concrete*** *project). Where relevant, please quantify your specific contribution. Please note that your project might be contributing to only some of these EU objectives and strategies to which the overall IPCEI contributes.*

1. Research, Development, Innovation and First Industrial Deployment (points 22-24 of the IPCEI Communication) 
   1. R&D&I Projects before IPCEI (for developing the IPCEI-project’s outcome at earlier research stages)

*Please provide the description of prior R&D&I activities, which were necessary for your planned individual IPCEI project and were carried out before the start of this project. Exclude any possible overlap in funding of previous R&D&I projects with the IPCEI project. Please, explain in this section the concrete link with the previous R&D&I activities, including project scope, duration, and context (i.e., EU project, national project, grantor, cooperation project, carried out solely with private financing etc.) as well as the concrete inputs of this previous R&D&I to this IPCEI project.*

*If you have no prior R&D&I project(s), please explain why.*

Please fill in the table below (when applicable).

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Previous R&D&I Project** | **Context** | **Period** | **Project scope** | **Contribution to your IPCEI project** |
| *Name of project, cost, if applicable the level of received support* | *e.g.,* *National, EU, cooperation project* | *Start, Duration, End* | *Indicate project scope, partners names, etc.* | *Give the concrete inputs used for your planned IPCEI project* |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |

Table 1: R&D&I projects before this IPCEI

* 1. R&D&I and FID activities in the IPCEI project

*For this section, please provide clear explanations about the technical aspects of your envisaged project in appropriate detail and avoid general/generalized statements. Limit yourself to a precise description on substance of your envisaged R&D&I and FID activities, clearly describing what and why makes it innovative beyond the GSOA.*

*Please provide in an annex a glossary of all abbreviations and short explanations of the technical terms in layman’s language.*

* + 1. Overview of the project
       1. Final outcome and objectives of the project

*Please point out clearly what is* ***the final outcome*** *of the project, i.e., what is to be developed (what product/service/process/technology). Explain who the customers/users of this outcome will be.*

* + - 1. R&D&I and FID, objectives, challenges and approach to overcome challenges

*Explain* ***the research and development objectives*** *of your project to reach the above outcome. These objectives must be linked to the descriptions in section 2 of the PP.*

*Explain the R&D&I and FID challenges which your project aims to overcome in order to meet the objectives pursued.*

*Please explain the proposed approach to achieve the objectives and overcome the challenges.*

* + - 1. Structure of the project

*Please provide a clear structure of your project in WP, also clearly separating and indicating which are the R&D&I and which are the FID WP. Clearly separate the FID activities in a separate WP.*

*Provide and explain specific milestones for each WP****.***

* + 1. GSOA that concerns your project

*Please describe to the best of your knowledge and available market intelligence, the current GSOA and provide clear, measurable/quantifiable technical key performance indicators (KPI) etc., quoting appropriate references to measure such GSOA. Please note that the same specific targets will also be used to demonstrate how your IPCEI project will exceed current GSOA and by how much****.*** *Assumptions and explicit definitions (e.g., system boundary, operation conditions, etc.) should be provided whenever necessary for clearly defining the relevant KPIs.*

* + 1. R&D&I part of the project
       1. R&D&I activities of the project

*Please describe the research and development activities to be performed in each WP of your project in sufficient scientific and technical detail to enable understanding also by non-experts, for a meaningful assessment. Avoid splitting up the description in numerous small innovations where these are parts of one overarching innovation. Please also describe the aim/outcome of the research to be performed in each WP upon which the research in the next WP will continue. Please provide clear descriptions and detailing the expected milestones achieved in each of the phases.*

*Please provide and justify relevant KPI that will demonstrate the accomplishment of innovative goals of the research and development activities and their aims in a given WP in order to proceed with the activities in the next WP.*

*Outline the total duration of the research and development part (including of each WP) of the project.*

*Please specify the same for FID-relevant KPIs and how R&D&I actions will lead to FID ones.*

* + - 1. Major innovative nature of the project

*Please demonstrate the major innovative nature of the project by justifying how the project aims at delivering an outcome beyond the GSOA, thereby constituting an important added value compared to GSOA.*

*Please also provide a comparison between your project and the GSOA in measurable/quantifiable specific characteristics (milestones / KPI etc.) of those aspects and demonstrate the major innovative nature or the important added value at the level of the overall individual project, as well as per WP, where relevant.*

*Please describe why going beyond the GSOA is technically challenging (note that the fact that the project is important for the company is irrelevant; the justification should be related to the sector and the related technology to be developed)****.***

* + 1. FID part of the project

*Present the FID activities in a dedicated WP(s) of your project. For this WP ‘FID’ demonstrate:*

* + - 1. FID activities

*Please provide a full list and a short, yet meaningful, description of the FID activities.*

* + - 1. Compliance of the FID activities with the IPCEI Communication criteria

*To demonstrate the compliance of the FID activities (as listed in the preceding sub-section) with the criteria in points 23-24 of the IPCEI Communication, for each FID activity demonstrate in specific terms the below conditions. Please note the novelty* ***of the FID activities*** *must also go beyond the GSOA.*

* 1. *How your FID activity follows on from an R&D&I activity that is also described in the PP (please make reference to the above sub-section 3.2.3 or to section 3.1 if your project consists only of FID);*
  2. *How it allows for the development of a new product or service with high research and innovation content or the deployment of a fundamentally innovative production process;*
  3. *Why your FID activity is not about mere regular upgrades without an innovative dimension of existing facilities or the development of newer versions of existing products;*
  4. *How it involves the upscaling of pilot facilities, demonstration plants or first-in-kind equipment and facilities covering the steps subsequent to the pilot line including the testing phase and the bringing of batch production to scale;*
  5. *Describe and justify how each FID activity itself contains an important R&D&I component which constitutes an integral and necessary element for the successful implementation of the project.*
  6. *In case your IPCEI project* ***only encompasses the FID phase****, in addition to all other information requested, please clearly demonstrate and provide evidence for the following (you may also make reference, where necessary, to section 3.1):*
  + *You have acquired the rights to use the results from the previous R&D&I activity. Please specify, who conducted that R&D&I;*
  + *Describe clearly both such preceding R&D&I activity and the FID in the project and submit evidence (where necessary).*
    - 1. Duration of FID and KPI

*Point out the duration of the FID part of the project.*

*Please explain the R&D&I-related criteria determining the end of the FID part of the project (and thus the transition to the mass production).*

*Describe and justify the quantifiable/measurable R&D&I-related (i.e., related to the important research that needs to be performed during the upscaling in the FID in order to reach, for instance, the quality of product, durability, compatibility, energy consumption, safety, environmental impact, etc.) KPIs for the end of the FID phase and demonstrate how and when they will be reached****.***

* + - 1. Sales during FID

*Please describe and explain planned sales during FID.*

*Explain about the sales during FID:*

* *the nature and purpose of these sales (e.g., for the purpose of delivering test samples, or for feedback purposes, or for certification, etc.),*
* *are such sales typical for this sector and why,*
* *why they are necessary (for instance, is there any customers’ feedback which is necessary to trigger additional research into the FID phase, and what is the quantity (in number of the items sold) necessary for such purposes,*
* *how/in what they differ from the ‘normal’ commercial sales during the mass production phase (for instance, are the products sold under different conditions in any way from commercial products, what are the terms of sales and how do they differ from those during the commercial phase), who bears the risk of these FID phase products*

*Describe about the sales during FID:*

* *the customers,*
* *the volume of the sales (number of units sold) annually during FID,*
* *the unit’s price,*
* *what will be the expected annual revenues during the FID out of these sales.*

*Please substantiate all the above assumptions with due evidence (e.g., (draft) agreements, offers, etc.). A lower level of evidence can be accepted especially in the case of projects by SMEs, should they find it more difficult to collect the necessary information.*

*In case you claim that you will not receive any payment from your customers for supplying them such (test/sample) items, thus having no revenues from sales during FID, in addition to the above please explain whether such practice ‘for free’ is customary in the industry/sector and for your company and provide due evidence (including for instance, original exchanges or agreements, etc. with the external actors involved in your FID activities.*

*This data and explanations must be coherent with the FG template.*

* 1. GANTT chart

*Include here a GANTT and schematic of the project showing how all the phases develop and end. This will help to illustrate and clarify boundaries (between R&D&I / FID and mass production phases). Therefore, it has to be consistent with the information provided throughout the PP and in the FG template.*

1. Necessity (incl. incentive effect) and proportionality of the aid

*The information in this section complements and explains the figures as presented in the FG template and aims at verifying that the aid is needed for the project and proportionate.*

* 1. Incentive effect

*Please state the date at which the aid application was submitted to the national authorities and the (envisaged) date of starting the works on your project.*

*Please confirm that the project would not in itself be sufficiently profitable for your company to undertake without aid. Please clearly explain your incentive to carry out the project with the planned aid amount, particularly, if significant amounts still need to be found elsewhere (e.g., private funding or other national or EU funding) to close the funding gap.*

* 1. Necessity of the aid

*Please explain why the aid is needed for your project by comparing the expected outcome and level of intended activity of your company with and without State ‘point 30 of the IPCEI Communication). The situation without the State aid is referred to below as the counterfactual scenario.*

*The counterfactual scenario must be described in sufficient detail: which activities or investments would you undertake if you would not receive the requested State aid, and to what extent would your project still be realised without the aid (e.g., would the project be realised with a more limited size or scope or lower level of ambition, more slowly, later, or in a different manner, somewhere else or not at all)? Would the company undertake a different project, or no specific project at all and simply continue its business as usual?*

*For situations in which the counterfactual consists in an alternative project, your company has to also describe the factors affecting the probability of implementing the alternative project (e.g., availability of external funding, of sufficiently skilled workforce, levels of IP protection available in the alternative locations, considerations for security and timeliness of supply, regulatory framework, etc.).*

*Please substantiate the credibility of your counterfactual scenario by submitting authentic internal company documents which demonstrate the choices faced by your company and how the decision on whether to carry out the project was taken. These authentic internal company documents should be annexed to this PP and predate the aid application.*

*Referring to your explanation in section 7 of the PP, please also explain why market incentives or market signals alone cannot deliver a change to your behaviour.*

*In line with footnote 27 of the IPCEI Communication, in the case of projects by SMEs, it can be indicated here that their counterfactual scenario may consist in the absence of an alternative project.*

* 1. Appropriateness of the aid instrument

*Explain which aid instrument is requested (grant, repayable advance, loan, guarantee, etc.). Please justify why the proposed aid instrument constitutes the most appropriate policy instrument to achieve the objectives of your project. An aid instrument will not be considered appropriate if other less distortive policy instruments or other less distortive aid instruments (e.g., loans instead of grants) make it possible to achieve the same result.*

*Please explain also whether there are any policies and support measures in place that already address the market failures affecting your project, as identified in section 7 of the PP (e.g., R&D&I programs, CEEAG aid schemes, other regulations or policies). If additional policies and measures are already in place to address (some of the) market failures identified, please demonstrate why those instruments are not sufficient to address the market failures sufficiently.*

* 1. Proportionality of the State aid

*In this section, please describe and justify all costs and revenues expected during the lifetime of the project as well as all input parameters for the company’s calculations in the Funding Gap (FG) template (e.g., terminal value, WACC parameters, etc.). All assumptions and/or estimates on costs, revenues and input parameters for your funding gap calculation should be substantiated with appropriate evidence (e.g., price quotes from suppliers, quantitative benchmarks from previous similar projects, extracts from internal or public company documents, market studies, academic papers, relevant historical data, etc.)*

*Please ensure full consistency between the explanations and figures in the PP and the data provided in the FG template. Please indicate clearly in the PP where in the FG template the data can be found (e.g., name of Excel worksheet, row/column, cells) Formulas for custom calculations in the FG template should be explained and be consistent with the descriptions provided in the PP template. In the FG template, figures should generally not be hard-coded.*

*The financial projections for your project should cover the entire project period, i.e., the full lifecycle of the envisaged product or technology. For R&D&I/FID projects this means from the R&D&I phase for the product or technology in question, over the FID phase and the mass production phase, up to the final withdrawal from the market. Hence, the FG must also include revenues linked to the mass production phase.*

*Please note that when presenting and justifying the costs for your project, you are required to do so in two steps: as a first step you need to explain and justify the level of your costs (section 5.4.2 with sub-sections below) and, as a second step, to explain and justify the eligibility of the costs of the project (section 5.4.3 and its sub-sections below).*

*In the case of projects by SMEs, which might find it more difficult to produce the necessary justifications and evidence underpinning their projections, the level of evidence requested will be analysed consequently. In any event, and particularly in the absence of evidence, sufficient (but concise) information should be provided to allow a basic understanding of cost and revenue assumptions and other parameters used in the funding gap calculations of a project.*

* + 1. Requested amount of State aid

*Indicate the requested State aid amount both in nominal and discounted terms, and with guidance from your national authorities provide information on the anticipated yearly instalments. The aid should be discounted using the WACC as discount factor in the project’s funding gap calculation. The nominal aid should be lower than the eligible costs. The discounted aid should be lower than the funding gap of the project.*

* + 1. Costs of the project
       1. Costs of feasibility studies and of obtaining required permissions

*Please provide a brief description of the content and scope of the feasibility studies and link them to your project.*

*If you claim eligible costs for feasibility studies, please justify that the activities comply with the definition of a feasibility study, i.e., an evaluation and analysis of the potential of a project, which aims at supporting the process of decision-making by objectively and rationally identifying its strengths and weaknesses, opportunities and threats, as well as identifying the resources required to carry it through and ultimately its prospects for success. Please note that these costs cannot include the costs of R&D preceding your project.*

*If you claim costs for required permissions, please justify how these are necessary for the realisation of your project.*

*Please provide a breakdown of these costs per project phase and per WP by filling in the overview table below. All figures provided should be fully consistent with those in the FG template.*

|  |  |  |  |
| --- | --- | --- | --- |
| Type | Costs (EUR) | Year of occurrence | WP of your project |
| *Examples (please delete when filling in):* |  |  |  |
| *Feasibility study* | *10 000* | *2022* | *2* |
| *Environmental permit* | *5 000* | *2024* | *2* |
| *Total:* |  |  |  |

Table 2

* + - 1. Costs of instruments and equipment

*Please provide a brief description about the type and* *purpose of the instruments and equipment needed for your project.*

*Please also indicate the capacity of the production equipment (e.g., in terms of output capacity).*

*Clarify the depreciation period and method applicable to each type of instrument or equipment and justify it with reference to your company’s usual depreciation practices (which should be demonstrated with an extract of your financial statements).*

*Indicate for which WP(s) of your project the instruments and equipment will be used.*

*If you do not use the equipment and instruments fully (100%) for your project (i.e., they are not dedicated to your project but shared with other activities), then clarify and quantify (based on suitable indicators) the extent to which the instruments and equipment will be used for the purposes of your project. Note that costs for these assets can only be included in your funding gap calculation in proportion to the extent the assets are used for your project.*

*The expected costs of instruments and equipment must be duly justified by supporting documents (e.g., offers from suppliers, catalogues with price lists, evaluations, commercial correspondence with suppliers and contractors, preliminary contracts, etc.). High-level estimates are generally not considered sufficient as evidence.*

*Please provide a breakdown of these costs per project phase and per WP by filling in the overview table below. All figures provided should be fully consistent with those in the FG template.*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Description of equipment and instruments | Number of equipment and instruments | WP of your project | Investment costs (EUR) | Investment year | Depreciation period | Usage in % for your project |
| *Example: Wet Chemical Bank, RIE Equipment* | *5* |  | *2 000 000* | *2024* |  | *80%* |
| \*\*\* |  |  |  |  |  |  |
| Total: |  |  |  |  |  |  |

Table 3

* + - 1. Costs of the acquisition or construction of buildings, infrastructure and land

*Please provide a brief description about the buildings, infrastructure and land needed for your project and clarify their purpose. Please also indicate the size of the buildings, infrastructure or land (e.g., surface in m²).*

*Clarify the depreciation period and method applicable to buildings and infrastructure and justify it with reference to your company’s usual depreciation practices (which should be demonstrated with an extract of your financial statements).*

*Indicate for which WP(s) of your project the buildings, infrastructure and land will be used.*

*If you do not use the buildings, infrastructure or land fully (100%) for your project (i.e., they are not dedicated to your project but shared with other activities), then clarify and quantify (based on suitable indicators) the extent to which the instruments and equipment will be used for the purposes of your project. Note that costs for these assets can only be included in your funding gap calculation in proportion to the extent the assets are used for your project.*

*The expected costs of instruments and equipment must be duly justified by supporting documents (e.g., offers from suppliers, catalogues with price lists, evaluations, commercial correspondence with suppliers and contractors, preliminary contracts, etc.). High-level estimates are generally not considered sufficient as evidence.*

*Please provide a breakdown of these costs per project phase and per WP by filling in the overview table below. All figures provided should be fully consistent with those in the FG template.*

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Description of buildings /infrastructure/  land | Investment costs (EUR) | Investment year | Depreciation period | WP of your project | Capacity of the buildings  /infrastructure/  land | Usage in % for your project |
| *Example only (please delete when filling in):*  *Clean Room* | *10 000 000* | *2025* |  | *2* |  | *10%* |
| \*\*\* |  |  |  |  |  |  |
| Total: |  |  |  |  |  |  |

Table 4

* + - 1. Costs of other materials, supplies and similar products necessary for the project

*Please provide a description of the materials, supplies and similar products which are expected to be needed for your project. Indicate for which activities they are needed in which WP and when. Explain and justify how they are directly associated to the project.*

*Please substantiate the expected costs for the needed materials, supplies and similar products. Provide a measure of the needed volume and the unit price for all types of materials, supplies or similar products needed. Please substantiate these cost assumptions with appropriate evidence (e.g., offers from suppliers, technical specifications, draft contracts, etc.) and justify the volumes.*

*Please provide a breakdown of these costs per project phase by filling in the overview table below. All figures provided should be fully consistent with those in the FG template.*

For R&D&I/FID projects:

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Type | Unit Cost | Volume during RDI | Volume during FID | Volume mass production | Cost during RDI | Cost during FID | Cost during mass production | Total costs for the lifetime of the project |
| *Examples (please delete when filling in):* |  |  |  |  |  |  |  |  |
| *Electricity* | *EUR 40/MWh* |  |  |  |  |  |  |  |
| *Chemical A* | *EUR 100/ton* |  |  |  |  |  |  |  |
| *….* |  |  |  |  |  |  |  |  |
| *Total:* |  |  |  |  |  |  |  |  |

Table 5

* + - 1. Costs of patents and contractual research

*Please provide a brief description of the subject of such contractual research, the contracting parties and justify why such research is outsourced and not done by your company. If you provide these details in the description of the related WPs, please include a cross-reference to the relevant section(s) of the PP.*

*Provide appropriate evidence for the costs claimed for contractual research and obtaining patents (e.g., draft contracts, number of researchers, person-months and average salaries). If applicable, demonstrate that the costs are set at arm’s length conditions.*

*Please provide a breakdown of these costs per project phase and per WP by filling in the overview table below. All figures provided should be fully consistent with those in the FG template.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| *Cost item* | *Type of cost (patent/contractual research/other)* | *Costs (M€)* | *WP* | *Period* |
| *Contract for research on material* | *Contractual research* | *100* | *2* | *2027-2030* |
| *…* |  |  |  |  |

Table 7

* + - 1. Personnel and administrative costs (including overheads)

*For personnel costs, please provide a breakdown in the number of full-time equivalents (FTE) or person-months and expected salary (per FTE or person-month), and this for each job profile or qualification level expected to be needed for your project. Please indicate for which WP they will be employed.*

*For administrative costs, please indicate what they consist of and justify how they were computed.*

*Please provide a breakdown of these costs per project phase by filling in the overview table below. All figures provided should be fully consistent with those in the FG template.*

For R&D&I/FID projects:

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Type of employee | Number | Wage per employee | Qualification level | Number of person months PM during RDI | Number of PM during FID | Number of (PM) during mass production | Cost during RDI | Cost during FID | Cost during mass production | Total costs during the lifetime of the project |
| *….* |  |  |  |  |  |  |  |  |  |  |
| *Total:* |  |  |  |  |  |  |  |  |  |  |

Table 8

* + - 1. Other costs

*If relevant for your project, please explain which other costs you claim and what they relate to.*

*Please provide a breakdown of these costs per project phase and per WP. All figures provided should be fully consistent with those in the FG template.*

* + 1. Eligible costs
       1. Eligible costs for R&D&I and FID project

*Elaborating on the costs substantiated under section 5.4.2 above, please provide and justify the eligible costs of your project with respect to one of the cost categories listed below (taken from the Annex to the IPCEI Communication).*

*Eligible costs (including depreciations) only cover costs directly incurred for the purpose of and during the R&D&I and FID phases of your IPCEI project. You should therefore explicitly state the duration and cut-off date of the R&D&I and FID phases. This must be coherent with the information in the FG template and the information in the other sections of this PP template where you refer to it (notably (sub-)sections 5.4.2.3). Costs incurred during the mass production phase are never eligible.*

*a) Feasibility studies and costs of permits: For the R&D&I and FID phases, make sure to only include costs of feasibility studies and costs for permits directly related to one of the WPs of the R&D&I and FID phases, as described in section 3.2 above. The information you provide must be consistent with the information in section 5.4.2.3 of this PP template.*

*b) and c) equipment, instruments and buildings: Only the depreciation costs of buildings and the depreciation costs of instruments and equipment incurred during the R&D&I and FID phases and to the extent used for those phases constitute an eligible cost for R&D&I/FID projects under points 22-24 of the IPCEI Communication. The information you provide must be consistent with the information in sections 5.4.2.1 and 5.4.2.2 of this PP template.*

*d) Materials & supplies: Only the costs of materials & supplies incurred during the R&D&I and FID phases and to the extent used for those phases constitute an eligible cost for R&D&I and FID projects. The information you provide must be consistent with the information in section 5.4.2.4 of this PP template.*

*e) Costs of patents and of contractual research: Only contractual research and the licensing costs incurred during the R&D&I and FID phases and to the extent linked to those phases constitute an eligible cost for R&D&I/FID projects un. The information you provide must be consistent with the information in section 5.4.2.5 and 3.2 of this PP template.*

*f) Personnel costs and administrative costs, including overheads: Only costs directly incurred during the R&D&I and FID phases and to the extent linked to those phases constitute eligible costs for R&D&I/FID projects un. The information you provide must be consistent with the information in section 5.4.2.6 of this PP template.*

*h) Other costs: Only costs explained in sufficient detail, which do not fall in the preceding eligible costs categories, which are incurred during the R&D&I phase and to the extent it is demonstrated that they are inextricably linked to this phase, may constitute eligible costs for R&D&I/FID projects. Other costs incurred in the FID phase beyond those operating costs mentioned in (g) of the Annex to the IPCEI Communication) are not eligible. The information you provide must be consistent with the information in section 5.4.2.7 of this PP template.*

*The ‘Costs for FID’ as defined in letter g) of the Annex to the IPCEI Communication[[6]](#footnote-7) for the purpose of filling this PP are to be distributed within the other eligible cost categories as per above. Please clearly separate within each eligible cost category the costs relating to the R&D&I phase from the costs relating to the FID phase of the project and justify them separately for each part of the project.*

*Please summarise the eligible costs in the table below. Costs should be listed in a disaggregate manner for each R&D&I WP and for each FID WP. Note that the numbering of the types of eligible costs corresponds to the one in the Annex to the IPCEI Communication.*

|  | R&D&I phase | | | FID phase | | | Total |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Eligible costs | WP 1 (of your project) | WP ... (insert a column for each R&D&I WP) | Total for R&D&I part of the project | WP …( of your project) | WP….. (insert a column for each FID WP) | Total for FID part of the project | Total for the project |
| a) Feasibility studies, costs of obtaining the permissions required |  |  |  |  |  |  |  |
| b) Depreciation costs for instruments & equipment |  |  |  |  |  |  |  |
| c) Depreciation costs for buildings |  |  |  |  |  |  |  |
| d) Costs of materials & supplies |  |  |  |  |  |  |  |
| e) Costs for patents, intangible assets & contractual research |  |  |  |  |  |  |  |
| f) Personnel & administrative costs, including  overheads  of which:  Research personnel costs |  |  |  |  |  |  |  |
| h) Other costs (for R&D&I) |  |  |  |  |  |  |  |
| TOTAL ELIGIBLE COSTS |  |  |  |  |  |  |  |

Table 10: Eligible Costs (R&D&I and First Industrial Deployment)[[7]](#footnote-8)[EUR]

* + 1. Duration of mass production phase or operational phase

*Please substantiate the duration of the mass production phase of your R&D&I/FID project. Provide sound justification for it, submitting appropriate evidence (e.g., market reports, usual duration of product lifecycle, authentic internal company documents).*

*Please note that the absence of a mass production phase or operational phase for your project cannot be accepted. Also, the assumption of an overly short mass production phase or operational phase without any justification cannot be accepted.*

* + 1. Revenues and cost savings in mass production phase or operational phase

*Please explain in detail the assumptions used to estimate your revenues. Justify the volumes of sales you project for this stage. To this end, please describe: expected customers, annual quantities of sales (number of units sold) and sales unit price. Also, provide a calculation of your revenues as the multiplication of the unit price and sales volume (i.e., number of units sold). Explain your assumptions regarding the unit price and sales volume throughout the project’s lifetime and provide appropriate evidence to justify them (e.g., market forecasts and intelligence, past experience with the projects concerning similar technology, etc. ). Please also justify the gross margin level of your project, showing that it is in line with similar business activities. A detailed calculation of the revenues in Excel format should be provided in the FG template.*

*Note that projects can have more than one revenue stream (e.g., revenues also from IP licensing, sale of additional related services). Please distinguish and substantiate all revenue streams for your project.*

*Cost savings expected as a result of your project should also be considered as a revenue stream. Describe which cost savings are expected and when, how they derive from the project and how they are associated to the project’s results.*

*Please note that the absence of revenues during the mass production phase or operational phase of your project cannot be accepted. Uncertainty on future sales or revenues is not a valid justification for not including revenues. The projections of future revenues have to be realistic (i.e., not overly pessimistic nor optimistic) and reflect the fact that you are a profit-maximising entity that performs commercial activity.*

* + 1. Aid beneficiary’s weighted average cost of capital (WACC)

*Please provide the explanations and evidence for the calculation of the company’s WACC in the FG template. The WACC used should be the one relevant at the time of the pre-notification. Project-specific risk premiums should not be included in the WACC. Your WACC calculation should follow the capital asset pricing model (CAPM) approach as foreseen in the FG template, which should not be modified.*

*Please make sure to provide in the PP and FG template not only the input parameters necessary to calculate the WACC, but also the data sources used, with their description and a reference or link to the specific document or dataset from which data was taken. Please make sure to refer to objective and verifiable sources (e.g., observable market variables for the risk-free rate, extracts from your financial reports displaying the cost of debt and funding structure). When WACC parameters are not readily available for a given company (e.g., the beta for unlisted companies or equity risk premium), you may use the datasets of Aswath Damodaran [[8]](#footnote-9) for sector- or country-specific benchmarks.*

* + 1. Terminal Value (TV)

*The financial projections for your project should cover the entire project period, i.e., the full lifecycle of the envisaged product or technology. For R&D&I/FID projects this means from the R&D&I phase for the product or technology in question, over the FID phase and the mass production phase, up to the final withdrawal from the market. When the forecast period for which financial projections are provided in the FG template does not fully cover the entire mass production/operational phase or its exact duration is not known, a terminal value (TV) must be included in the last year of the forecast period to reflect cashflows that are expected to be generated beyond the forecast period in the funding gap calculation.*

*Hence, calculate a TV using the Gordon Growth Formula (GGF) provided in the FG template to capture any additional cashflows after the forecasting period. Please explain the assumptions used to determine each parameter of the GGF and provide appropriate evidence to substantiate them.*

*If (and only if) the projections cover the entire expected lifecycle of the product or technology and the project’s assets will not be reused (even with some refurbishing or modifications) for other purposes (e.g., a next technology), the TV can be calculated as the residual book value (RBV) or the sale price of the project’s assets (whichever is higher).*

*For R&D&I/FID projects, should the know-how or results obtained in your IPCEI project contribute to the development of the next generation of the product or technology in question, these benefits should also be explained, quantified and reflected in the TV (e.g., reduction of the R&D&I costs for the next generation).*

* + 1. Taxes

*Explain the corporate tax rules that are applicable to your company. Describe how taxation will affect the financial projections for your project and how tax effects have been modelled in your FG template. Provide the tax liability with and without the aid. Both tax liabilities (in years in which the project is expected to incur a profit) and tax savings (in years in which the project is expected to incur a loss which reduces your overall taxable income) should be taken into account. The tax rate applied in your financial projections should be consistent with the one used for the WACC calculation (see section 5.4.6).*

* 1. Other public funding (including EU funding) and State aid cumulation

*Explain whether your project also applied for or receives other public funding, including other State aid or Union funding (such as the Innovation Fund or Horizon Europe programmes). Indicate the source and the amount of such other public funding. Clarify whether such other public funding covers the same eligible costs as the expected IPCEI aid.*

*In case such other public funding is expected for the same eligible costs, provide a commitment that the total amount of public funding granted does not exceed the funding gap.*

* 1. Claw-back mechanism

*Please note that the aid is likely to be subject to a claw back mechanism.*

* 1. Co-financing

*As a general rule, IPCEI projects must involve important co-financing by the aid beneficiary. M*

*Therefore, please describe how your company will provide an important contribution to the financing of the project through private sources of funding (e.g., own revenues, equity, debt).*

*Please also calculate the degree of co-financing as the ratio of the requested aid amount to the most negative cash balance[[9]](#footnote-10) expected for your project.* *Please calculate the degree of co-financing both in nominal terms (using the requested aid amount and most negative cash balance in nominal terms) and in discounted terms using the requested aid amount and most negative cash balance in discounted terms).*

*Absence of important co-financing can be accepted for SMEs. However, the circumstances for the extent and possible absence of important co-financing should be properly substantiated and adequately motivated.*

1. Integration of the project in the IPCEI

*In this section you have to demonstrate that your company / your project contributes* ***concretely and specifically*** *to the integrated character of the IPCEI (e.g., integration into a common structure, roadmap or programme, systemic approach of the Member States that agreed to go ahead with setting up the IPCEI as described in the Chapeau that includes the overall work plan and aims at achieving common objectives,* ***complementarity and significant added value of the individual projects*** *therein) should also be demonstrated at the level of the individual components (projects between companies or individual company projects). Your project must fit within the objectives of the IPCEI and complementarity between the companies’ activities and activities of other direct partners must be demonstrated, as well as the significant added value of the individual project to the IPCEI and EU objectives.*

*Joint knowledge dissemination are not sufficient to demonstrate the integration of the projects. Also, the mere fact that participants are affiliated to the same standardization bodies is not sufficient to demonstrate integration.*

* 1. Insertion in a common structure, programme, roadmap

*Explain concretely how your project fits into the scope, objectives of the IPCEI.*

*Please also fill in the table below.*

|  |  |  |
| --- | --- | --- |
| **Individual project objectives and scope** | **IPCEI related objectives and scope** | **IPCEI associated deliverable(s)** |
|
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

Table 12: Overview of the project’s integration into the IPCEI

* 1. Contribution of the individual project to the integrated IPCEI
     1. Significant added value of the project

*Please describe how your project concretely contributes to and significantly adds value for the achievement of the goals of the IPCEI to which it is participating and thus – to the achievement of the European objective pursued by the IPCEI. To this end, please provide short but concise information. This section shall not describe the project but rather focus on explaining its concrete contribution in a clear and easy-to-understand language.*

* + 1. Complementarity of the project

***For R&D&I and FID projects:***

*Please describe how your project is complementary to the other individual projects in the IPCEI (please do not refer in this section to the planned collaborations as these will be addressed in section 6.3). Please note that mere collaborations on knowledge dissemination are not sufficient to demonstrate complementarity. Collaboration on standardization is also not sufficient to demonstrate complementarity when it corresponds to the usual work on standardization within standardization bodies.*

*Provide short but concise information in a clear and easy-to-understand language on how your project* ***is interlinked*** *with other individual projects. To this end, please identify the projects within the IPCEI to which the project described in the PP is* ***directly*** *complementary and describe this complementarity.*

* 1. *Please demonstrate to what extent the projects of your partners (direct participants in the IPCEI) are relevant for the implementation and success of your own project, with concrete examples. and explain in particular what would happen to your project if your partners’ project were not carried out.*
  2. *Conversely, please demonstrate the relevance of your own project to the successful implementation of the projects of your partners (direct participants in the IPCEI) and explain in particular what would happen to your direct partners’ projects if your own project were not carried out.*
  3. *Please indicate the planned timeline for implementing this complementarity of the projects in a consistent manner with each company’s work plan. Each company’s activities should be described in clear terms.*

*In addition, please provide a summary of this information in the following table (in the case of projects by SMEs, it is required to* ***only*** *report your information in this table):*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Other IPCEI project to which your project is complementary** | **Type of complementarity** | **What would happen to your project if your partner’s project were not taking place?** | **What would happen to your partner’s project if your project were not carried out?** | **Timeline of the different projects concerned** |
|  |  |  |  |  |
|  |  |  |  |  |

Table 13: Overview of complementarities

* 1. Collaborations with IPCEI Direct Participants

*Please describe in this section:*

* *The* ***important IPCEI-specific cross-border collaborations*** *that your company / your project has entered with other IPCEI direct participants for delivery of their IPCEI individual projects. Each collaboration must be described in concrete terms and with sufficient details, as described below.*

*For individual R&D&I and FID projects (integrated into an IPCEI based on p.22-24 of the IPCEI Communication) the cross-border collaboration must be* ***effective****; for the purpose of this template, effective collaboration is understood as collaboration between at least two independent parties to achieve a common objective based on the division of labour where the parties jointly define the scope of the collaborative project, contribute to its implementation and share its risks, as well as its results; contract research and provision of research services are not considered forms of collaboration), and their subject cannot be contractual research (performance of a research service or sub-contracting), neither simple supply/delivery relationships.*

* + *The purpose of the so called ‘matching events’ that are organized is precisely to help you establish such* ***cross border (within the EU)*** *meaningful collaborations.*
* *These cross-border collaborations should be:*
  + *Related to the scope and the objectives of the IPCEI.*
  + *IPCEI-induced (i.e., established due to this IPCEI) or IPCEI–enhanced (if a collaboration with the same company existed already before this IPCEI – how is this collaboration enhanced in its subject, scope, intensity or speed, due to the IPCEI),*
* *Other collaborations with direct participants.* 
  + *These other collaborations must relate to the scope and the objectives of the IPCEI and be either IPCEI-induced or IPCEI–enhanced and this should be justified.*
  + *For individual R&D&I and FID projects (integrated into an IPCEI based on p.22-24 of the IPCEI Communication) other collaborations with direct participants must also be* ***effective****;*
* *Please include also a table of the collaborations, with at least the following information: names of the collaborating* ***IPCEI direct participants****, type (small, medium or large* *enterprise), subject of the collaboration and to what extent the collaboration corroborates the complementarities between projects described in section 6.2.2, the IPCEI-induced or-enhanced nature of the collaborations, and a description of the tasks, works and contributions of each collaboration partner. The table should include both cross-border and other types of collaborations with direct participants.*
* *Evidence of the existence, subject and scope of such collaborations, as well as of the tasks of the collaboration partners must be provided (such as Letter of Intent, Memorandum of Understanding or other appropriate document duly agreed by both partners) as annexes to the PP. In case the negotiations between the collaboration partners have not reached signing of a collaboration agreement yet, please point out when this is expected. In case of inability to provide an agreement at the stage of formal notification, please describe alternative means of effective delivery of the subject of the collaboration and its de-facto performance.*

*Please also fill the table below (in the case of projects by SMEs, it is required to* ***only*** *report your information in this table):*

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Related direct Participant** | **Organization**  **Type** | **Objective of Cooperation** | **Subject and Scope of cooperation** | **Collaboration category** | **(For RDI and FID projects: Is the collaboration effective? If yes, how?)** | **What is the evidence of the collaboration (contract, LoI, etc.)** | **Timeline for implementing the collaboration** |
| *Name, Member State* | *LE, SME, Start-up* |  | *Relation with the individual project of the partner;*  *Tasks, works, contributions of each cooperation partner; Describe if your project will deliver an input to another partner’s project or will receive input from another partners’ project* | *IPCEI-induced or IPCEI-enhanced* |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |

Table 16: Cooperation with IPCEI direct participants

1. Market failures affecting the individual project

*A market failure is an inefficient market outcome (from the point of view of maximising social welfare and not only benefit an individual company) due to specific features of a market for goods and services. As part of demonstrating the market failures affecting your project, it is important to justify why the market on its own would not provide the desired outcomes from the point of view of maximizing social welfare.*

*In this section, please provide information if your IPCEI project is affected by any of the market failures listed (and briefly described) below. After explaining the specific market failure that affects your specific project, please specify respectively how the state aid for your specific project as part of the IPCEI would be appropriate to address them.* (*Please note that the mere existence of market failures is not sufficient to prove the necessity of State aid.)*

* 1. Negative externalities

*Negative externalities may occur, e.g., when a company does not bear the full cost of the harm they impose on society.*

*An example includes negative environmental externalities where companies do not bear the full cost of pollution they impose on society, which leads them to the use of more polluting/energy consuming/etc. technologies. In this context, the objective of State aid would be to promote ‘cleaner’/’less energy intensive’/’less polluting highly innovative’ etc. technologies.*

*Please note that here it is necessary to demonstrate how the technology or solutions developed by your project would lead to a use of a ‘better’ technology than what would otherwise be used in terms of, for instance, environmental effect. This must be duly justified. In this regard, please note that the simple support for the reduction of CO2 emissions by modernizing production processes/regular updates cannot be addressed in an IPCEI (see point 23 IPCEI communication), but may fall under other set of rules (e.g., Guidelines on State aid for climate, environmental protection and energy - CEEAG[[10]](#footnote-11)).*

* 1. Positive externalities

*Positive externalities may occur, e.g., when a company provides benefits to society, which it does not fully internalize.*

*An example of positive externalities is when a company’s innovation efforts may benefit other companies because new knowledge diffuses outside the company providing R&D, through social and business interactions, for instance in the form of regional development, or because of employees moving across companies. However, neither are all benefits of R&D&I activities externalities, nor does the presence of externalities alone justify State aid. In general, users/consumers are willing to pay for the direct benefit of new products and services while companies can appropriate the benefits from their investment through other existing instruments, such as intellectual property rights. In some cases, however, those means are imperfect and leave a residual market failure that may be corrected by State aid.*

*Please note that positive externalities are different from positive spillover commitments as mentioned in the IPCEI communication: positive externalities are the wider social benefits inherent to your specific project, not just the actions you commit to share the outcomes of you project.*

* 1. Coordination failures

*Coordination failures may prevent the development of a projects or its effective design due to diverging interests and incentives among investors. As an example, this is the case when multiple actors must simultaneously invest and ramp up production in order to commercialize a new technology.*

*Coordination failures may also stem from the need to reach a certain critical mass of investors before it is commercially attractive to start a project.*

*The strategic interaction between the various necessary actors may then require State intervention to coordinate actions and align incentives, in order to deliver R&D&I or to accelerate investments.*

*Please note that organisational complexity, managerial issues and firm-specific inefficiencies are not in itself a coordination market failure.*

* 1. Asymmetric information

*When companies or potential innovators are better informed than investors (or banks) about the true prospects of their projects, companies may face difficulties to convince investors (or banks) about the prospects of their projects and ultimately lack access to capital.*

*Please note it is important to provide project-specific arguments of why the investors and banks may not be able to appropriately assess the value of your project, thus providing for the financing necessary for it on market terms. Please support your claims with appropriate evidence (e.g.: correspondence and refusal to grant a loan / guarantee from a commercial bank). The threshold for demonstrating a lack of access to capital is anticipated to be more stringent for large companies in comparison to SMEs.*

*In addition, in case State aid takes the form of direct grants, it is necessary to justify how loans instead would not be sufficient to alleviate asymmetric information.*

* 1. Other market failures

*Please add any other significant market failures that your specific project may be experiencing and addressing.*

*Please bear in mind that that organisational complexity, business difficulties, technical complexity, uncertainty, or company-specific inefficiencies are not in themselves a market failure.*

1. Spillover effects

*In this section, please provide clear and straightforward commitments to actively deliver positive spillover effects. These should spread the benefits of your project beyond your company (=aid beneficiary), beyond the sectors concerned of your business and beyond the financing Member State in which your project will be performed or the facility/infrastructure will be located (i.e., to be cross-border). The spillover effects have to be of wider relevance to the economy and society of the Union. To this end, each aid beneficiary will have to go the 'extra mile' as compared to its normal business activities and commit to activities and initiatives that go beyond its routine behaviour and beyond what your company will do in any case or as a standard practice, or as necessary to perform its project.*

*The spillover effects cannot correspond to an eligibility or compatibility condition that the project would need to meet in any event and cannot coincide with the objective or the scope of the individual project.*

*Please formulate spillover effects commitments that are concrete, specific, identifiable, definable and measurable. These should be formulated as active commitments to be delivered by the aid beneficiary (e.g., ‘We commit to publish …, We commit to perform …., We commit to provide…’, ‘We commit to license….’). The delivery on the specific quantified commitments will be annually reported by the aid beneficiary and monitored by the Commission.*

*The commitments for spillover effects have to be provided for each project and for each company / aid beneficiary. For each spillover effect, please demonstrate the concrete link to your project (e.g., how the committed action will spread the knowledge and skills generated through your project that is supported by State aid) and the value added to the other (non-IPCEI participating) businesses, universities, research organisations and other stakeholders. Always describe the types of addressees of such spillover effects activities.*

*Do not propose as spillovers self-beneficial, public-relation and marketing-type activities or activities that are necessary for the execution of your individual project. General communication, contacting general public and raising general awareness is also of little value, unless duly justified by very specific circumstances and going beyond the usual scope of such activities. The mere fact that you are affiliated to or (will) take part in the work of the same standardization bodies is not sufficient to demonstrate the required spillover effects.*

*Spillover effects commitments that would be valued would be, for instance, the ones that provide commitments to actively* ***disburse to/share******with******professionals*** *beyond the IPCEI direct participants the* ***scientific knowledge******and the******practical skills and know-how*** *generated during and after the execution of the IPCEI projects; such dissemination/sharing has to be* ***meaningful and practical*** *and should teach and* ***enable others, especially SMEs*** *(outside the IPCEI, including those that are not aided) to* ***benefit (i.e., to develop themselves and offer****) at least the essential, basic product or service (while competing on the premium services) through, among others, commitment to grant licenses on fair, reasonable and non-discriminatory (FRAND) terms.*

*One and the same activity should not be duplicated in the different sub-sections below for the different types of the spillover effects but should be committed to only once in its appropriate place.*

* 1. Spillover effects by wide dissemination of non-IP protected knowledge and results acquired in your project

*Examples:*

*Publications in scientific peer-reviewed journals, scientific conferences on individual IPCEI project’s generated knowledge results, collaborations with universities and research and knowledge dissemination organisations (ROs), targeted hands-on workshops and seminars.*

*This type of spillover effects would refer to the dissemination of scientific knowledge, the skills and know how created both in the R&D&I and FID phases. The target audience should comprise scientists from universities and ROs, scientific personnel and researchers from companies’ research departments, other professional audience.*

*Specify in concrete terms your involvement with ROs and the academic community (e.g., scope of collaboration, etc.).*

*If considering financing of university chairs, bachelor’s and master’s theses, Ph.Ds. (and/or post-doctoral theses) please name the respective universities, specify to the extent possible the scope of each sponsorship (e.g., titles of theses) and demonstrate there is a direct relation to the subject of your IPCEI project and how through such commitment you will be actively disbursing the scientific knowledge coming out of your IPCEI project. Please note that such sponsorship should not be limited to universities in your Member State but should also include cooperations with universities in other Member States.*

*In the case of scientific publications, please provide the list of these publications and the names of the respective journals, which would be made available in Europe.*

*When committing to participation in external events (such as scientific conferences) provide the concrete details (e.g., names of the events and year), and explain whether you participate as contributor (presenting the type and results of your research) or as organiser. The same applies to workshops and seminars organised throughout Europe and not only in the participating Member State.*

*However please note that the examples above are minimum basic dissemination activities, which in themselves are not sufficient to qualify as sufficient spillovers. Please go further (adding extra value in terms of quality) in your commitments.*

* 1. Spillover effects for IP-protected knowledge and results

*Please explain what knowledge and results coming out of your IPCEI project you expect to IP-protect (please note that this information has to be consistent also with the costs for patents you are claiming in Section 5).*

*Please commit concretely to licence on FRAND terms to any interested party in the EU the IP-protected knowledge and results of both the R&D&I / FID phases of your project (which were generated thanks to the State aid received).*

*If your project will objectively not generate any IP-protected knowledge, because for instance the outcome is planned to be released open source, please justify this (also considering specific circumstances of your IPCEI and/or economic sector(s)) and provide in this section your commitments for active delivery of spillover effects* ***that will surpass the normal/usual*** *(e.g., open-source) behaviour and will deliver additional benefits to the wider EU economy and society, SME competitors and users.*

*Please commit to deliver also other positive spillover effects related to IP-protected knowledge and results.*

* 1. Specific spillover effects in FID phase

*Examples:*

* *Providing access to FID facilities or equipment (e.g., clean rooms, labs, etc.) for other companies and especially to SMEs, start-ups, in order to enable them to develop their own projects. Please commit to the exact capacity to be opened up, to which entities it will be open, describe the terms for access and the active actions to attract such users.*
* *Specific hands-on training how to use/do/replicate the process, aimed at other companies to enable them to pursue their own business objectives.*

*Please commit to deliver* ***also other*** *positive spillover effects related to FID part of your project.*

* 1. Spillover effects through collaboration with indirect and associated partners

*Please describe the indirect partners, with whom you have collaborations. Please describe how and why they were selected. For each collaboration with an indirect partner, please describe in concrete terms and with sufficient details:*

1. *Who is the collaborating partner, explain its type (SME, Large Enterprise, research organization, university);*
2. *What is the subject of this collaboration, how is it related to your project and the IPCEI; whether it is IPCEI-induced or IPCEI-enhanced;*
3. *What are the tasks and works to be performed, and contributions of each collaborating partner;*
4. *What does the positive spillover effect consist of and what would happen to the potential indirect partners in the absence of your project.*

*Please provide evidence for the existence of such collaborations, (e.g., LOI, memorandum of understanding or some other appropriate document).*

*Please note that:*

* *The collaboration relations with the indirect partners, included in this section, for individual R&D&I and FID projects (integrated into an IPCEI based on p.22-24 of the 2021 IPCEI Communication), must be meaningful R&D&I collaboration and cannot be a simple supply/delivery relationship, subcontracting or contract research.*
* *You do not need to duplicate the collaborations listed in this sub-section as spillovers in the other spillover effects sub-sections. Instead, please chose, according to your views on the main area of importance or contribution, in which particularly spillover effects sub-section such a collaboration (especially with research organisations), should be included.*

*Please also fill out with summary information the table below:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Indirect partner** | **Type** | **Subject and Scope of collaboration** | **Collaboration category** | **What is the evidence of the collaboration (contract, LoI, etc** | **Timeline for implementing of the collaboration** |
| *Name, Member State* | *LE, SME, Start-up, RO,* | *Relation with the individual project of the direct partner; Tasks, works, contributions of each collaborating partner* | *IPCEI-related,*  *IPCEI-induced or IPCEI-enhanced* |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |
|  |  |  |  |  |  |

Table 17: Collaborations with indirect partners this IPCEI

* 1. Other spillover effects

*Please include here your commitments for spillover effects that are not covered by the previous sections, in other alternative sectors or value chains that are not targeted by the IPCEI (e.g., collaborative research projects for introducing the technology you have developed in a sector or application that differs from the scope of your project, providing manuals, practical guidance and training for companies on the application and adjustment of your project in other sectors for which it was not meant originally, etc.).*

* 1. Overview of spillover effects

*This section is to quantify the spillovers described above. Please note that you have to also allocate annual quantities of spillover effects to be delivered, that will be reported with your annual reports and monitored by the Commission.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Spillover effects (name)** | **KPI (appropriate to the type of spillover)** | **Target value without IPCEI[[11]](#footnote-12)** | **Target value with IPCEI** |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

Table 18: KPIs table for spillover effects

1. Compliance with the ‘Do no significant harm’ principle

*According to point 20 of the IPCEI Communication, Member States must provide evidence as to whether the project complies with the principle of ‘do no significant harm’ (DNSH) within the meaning of Article 17 of Regulation (EU) 2020/852, or other comparable methodologies.*

*To make it possible for the Commission to conclude on the compliance of the IPCEI with DNSH, please provide a reply to the below set of questions for your project.*

*Please note that your answers must concern your concrete IPCEI project. For activities for which technical screening criteria determining whether that economic activity causes no significant harm to any of the other environmental objectives have been established under delegated regulations supplementing Regulation (EU) 2020/852 of the European Parliament and of the Council, the justification should, in particular, be made by showing that the activity fulfils these technical screening criteria.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Questions** | **Yes** | **No** | **Justification of the reply**  ***(Note: please remove the guidance text, provided below in italic, when submitting the replies)*** |
| **Climate change mitigation:** Is the notified project expected to lead to significant GHG emissions? |  |  | *Questions to be answered:*   * *Please confirm if the activity will lead to significant GHF emissions? Please substantiate with evidence.* * *Please outline if the current energy needed for the project is from renewable or fossil fuel sources.* * *Will your project improve the energy efficiency of the current process? If so, please substantiate with evidence.*   *Additionally, where the project consists of manufacturing of electrical and electronic equipment:*   * *If the manufactured product contains refrigerants, please confirm that it complies with the GWP performance laid down in the Regulation (EU) No 517/2014 of the European Parliament and of the Council and that the activity does not manufacture products containing Sulfur hexafluoride (SF6).* * *Where applicable, the manufactured product does not score lower than the third significantly populated class of energy efficiency in accordance with Regulation (EU) 2017/1369 of the European Parliament and of the Council and delegated acts adopted under that Regulation.* |
| **Climate change adaptation:**Is the notified project expected to lead to an increased adverse impact of the current climate and the expected future climate, on the notified project itself or on people, nature or assets? |  |  | * *Questions to be answered:Please confirm which, if any, physical climate risks from the table in Section II of Appendix A, Annex II, of the Commission Delegated Regulation ‘C/2023/2486 final’ may affect the performance of the economic activity during its expected lifetime. If there is a risk identified, please assess the adaptation solutions that can reduce the identified physical climate risk.* |
| **The sustainable use and protection of water and marine resources:**Is the notified project expected to be detrimental:   1. to the good status or the good ecological potential of bodies of water, including surface water and groundwater; or 2. to the good environmental status of marine waters? |  |  | * *Questions to be answered:Please confirm if you are committed to conducting an Environmental impact assessment (EIA) in accordance with Directive 2011/92/EU and this includes a chapter on water. Where an EIA has already been conducted, in the area of water, please confirm that solutions will be imposed on any risks identified.* * *Please confirm that the activity will not hamper the achievement of good environmental status of marine waters or will not deteriorate marine waters that are already in good environmental status as defined in point 5 of Article 3 of Directive 2008/56/EC, taking into account the Commission Decision (EU) 2017/848 in relation to the relevant criteria and methodological standards for those descriptors.* * *Where an EIA will not be conducted, in the area of water, please outline the following:*   *(a) Is your project being conducted in a water scarcity area? if so, please outline how you will ensure the project will not add pressure to the current needs of this resource.*  *(b) Please outline if you will emit anything into water bodies? If so, please outline if the water will be processed and cleaned prior to its injection into water bodies.*  *(c) Will the project have a water use and protection management plan? What will this plan include?* |
| **The transition to a circular economy, including waste prevention and recycling:**Is the notified project expected to:   1. lead to a significant increase in the generation, incineration or disposal of waste, with the exception of the incineration of non-recyclable hazardous waste; or 2. lead to significant inefficiencies in the direct or indirect use of any natural resource[[12]](#footnote-13) at any stage of its life cycle which are not minimised by adequate measures[[13]](#footnote-14); or 3. cause significant and long-term harm to the environment in respect to the long-term disposal of waste? |  |  | * *Questions to be answered:Please confirm the following:*   *(a) If the activity assesses availability of and, where feasible, uses equipment and components of high durability and recyclability and that are easy to dismantle and refurbish.*  *(b) That your project has a waste management plan and that it prioritises recycling over disposal of waste.* |
| **Pollution prevention and control:**Is the notified project expected to lead to a significant increase in the emissions of pollutants[[14]](#footnote-15) into air, water or land? |  |  | *Questions to be answered:*  *Where the project consists of manufacturing of electrical and electronic equipment*  *Please confirm, for each of the points below, that your activity will not lead to manufacturing, placing on the market, or use of the following:*   * *substances, whether on their own, in mixtures or in articles, listed in Annexes I or II to Regulation (EU) 2019/1021 of the European Parliament and of the Council, except in the case of substances present as an unintentional trace contaminant;* * *mercury and mercury compounds, their mixtures and mercury-added products as defined in Article 2 of Regulation (EU) 2017/852 of the European Parliament and of the Council;* * *substances, whether on their own, in mixture or in articles, listed in Annexes I or II to Regulation (EC) No 1005/2009 of the European Parliament and of the Council;* * *substances, whether on their own, in mixtures or in an article, listed in Annex II to Directive 2011/65/EU of the European Parliament and of the Council, except where there is full compliance with Article 4(1) of that Directive;* * *substances, whether on their own, in mixtures or in an article, listed in Annex XVII to Regulation (EC) 1907/2006 of the European Parliament and of the Council, except where there is full compliance with the conditions specified in that Annex;* * *substances, whether on their own, or in mixtures or in an article, in a concentration above 0,1 % weight by weight (w/w), and meeting the criteria laid down in Article 57 of Regulation (EC) No 1907/2006 and that were identified in accordance with Article 59(1) of that Regulation for a period of at least 18 months, except if it is assessed and documented by the operators that no other suitable alternative substances or technologies are available on the market, and that they are used under controlled conditions.* * *Please confirm that the activity does not lead to the manufacture, presence in the final product or output, or placing on the market, of other substances, whether on their own, or in mixtures or in an article, in a concentration above 0,1 % weight by weight (w/w), that meet the criteria of Regulation (EC) No 1272/2008 for one of the hazard classes or hazard categories mentioned in Article 57 of Regulation (EC) No 1907/2006, except if it is assessed and documented by the operators that no other suitable alternative substances or technologies are available on the market, and that they are used under controlled conditions.*   *In case of manufacturing of portable batteries, please confirm that batteries comply with the applicable sustainability rules on the placing on the market of batteries in the Union, including restrictions on the use of hazardous substances in batteries, including Regulation (EC) No 1907/2006 and Directive 2006/66/EC of the European Parliament and of the Council.*  *Where the project consists of the Provision of IT/OT data-driven solutions*  *Please confirm that:*   * *the equipment used to operate the software meets the requirements laid down in Directive 2009/125/EC[[15]](#footnote-16) for servers and data storage products; and* * *the equipment used does not contain the restricted substances listed in Annex II to Directive 2011/65/EU [[16]](#footnote-17) , except where the concentration values by weight in homogeneous materials do not exceed the maximum values listed in that Annex.* |
| **The protection and restoration of biodiversity and ecosystems:** Is the notified project expected to be:   1. significantly detrimental to the good condition[[17]](#footnote-18) and resilience of ecosystems;or 2. detrimental to the conservation status of habitats and species, including those of Union interest? |  |  | * *Questions to be answered:Please confirm if your project is located in or near biodiversity-sensitive area (including the Natura 2000 network of protected areas, UNESCO World Heritage sites and Key Biodiversity Areas, as well as other protected areas). Where this is the case, please confirm you will conduct an appropriate assessment and confirm that any required mitigation and compensation measures for protecting the environment will be implemented.*   *Where the project consists of manufacturing of electrical and electronic equipment*  *Please confirm if you are committed to carrying out an Environmental Impact Assessment or screening in accordance with Directive 2011/92/EU. In the case where an EIA has already been carried out, please provide evidence, and outline the results along with your plans to rectify any issues.* |

Table 19

1. Limitation of undue distortions of competition and trade

*Please describe in this section in a detailed and comprehensive way if and in case why the State aid requested for your project will not lead to undue distortions of trade or competition (or does so only to a very limited extent – in such a case please provide adequate commitments to alleviate these concerns).*

*In the case of projects by SMEs, If there is no third party market data (e.g. market reports), companies can provide their best estimates.*

* 1. Markets affected

*Please identify and describe the main technologies/services/products developed by your project, their substitutes (existing or being developed), and identify the economic activities for which the technologies/services/products developed by the project will be used, both as a direct consequence of the project and as other potential and future applications. Identify the geographical boundaries of each of these markets (National/European/Worldwide). Identify your main competitors, your suppliers and customers. This information should be provided for all market segments on which you are active,* *including for the upstream, downstream and complementary markets if they may be affected.*

* *The upstream market is the market at the previous stage of the production/distribution chain, e.g., the production of motor vehicles would be an upstream market in relation to the sale of motor vehicles to final consumers.*
* *The downstream market is the market at the next stage of the production/distribution chain, for example, the distribution and sale of motor vehicles would be a downstream market in relation to the production of motor vehicle.*
* *The complementary market is the market that supports or enhances the primary market by providing related products or services, for example, in the case of motor vehicles, the sale of accessories.*

*For each market or segment potentially affected by State aid, please provide a descriptive analysis of the current and future (=after the IPCEI) market situation in terms of: stage of development, market volumes, active suppliers, main players; aggregate capacity, market shares, aggregate demand, and main customers (in case of SME, best estimates might suffice).* *Please also provide your descriptive analysis of your position on these markets or segments at present and after the IPCEI.*

*Please complement the above descriptive information with the following quantitative information provided for each market or market segment concerned, before and after the IPCEI, considering at the minimum the past 5 years of data and an estimate of the forward-looking 10 years of data:*

* *Total size (volume) and value (turnover in EUR) of these markets or segments;*
* *Your market position, including the total size (volumes) and value (turnover in EUR) of your activity in these markets or segments, and your market shares;*
* *Your main competitors and their market positions, your suppliers and customers in these markets or segments.*

*Only if your current core economic activities are different from the ones related to your IPCEI project, please also present the following information:*

* *What are the current core economic activities of your company and what is the already established position of your company on these markets.*
* *What is the relation between these current core economic activities and the new ones related to your IPCEI project, and between your already established market position on the markets you are already active, and the new ones related to your IPCEI project.*
* *What is the extent to which you deem your market position on the markets of your current core activities will be strengthened due to the new activities added and the extent to which you would be able to leverage your market strength on your current markets into the new ones. Please also provide your views why such cross-leveraging, if it would occur, would not lead to distortive effects on the competition and trade in the markets affected by the aid and commit to appropriate safeguards.*

*Please use as much as possible available third-party information complemented by the specific company’s project information as appropriate. Please also provide the sources of information you are using.*

*Please note that this information should be consistent with the Competition assessment template developed for the IPCEI.*

* 1. Limiting the negative effects on competition

*Please describe the foreseeable impact the aid may have on competition between companies in the markets affected by State aid, including upstream, downstream, and complementary markets.*

*In addition, examine the impact of the aid on the below competition distortions.*

* + 1. Limiting the risk of overcapacity

*Justify why the aid to your project will not lead to overcapacity in the affected markets or segments and provide possible commitments to avoid or alleviate these concerns.*

* + 1. Limiting the risk of foreclosure and distortion of dynamic incentives

*Input foreclosure arises when an upstream supplier with sufficient market power is able to soften downstream competition by profitably raising input prices or restrict supply for downstream rivals competing with its own vertically integrated downstream entity. Please provide an assessment of the impact of the aid on the risk of input foreclosure and possible commitments to avoid or alleviate these concerns.*

*Customer foreclosure arises when a downstream firm with sufficient market power reduces or stops procuring a substantial share of input from an upstream supplier competing with its own vertically integrated entity. To the extent that this reduces their ability and incentives to compete, downstream rivals may be faced with higher input costs. Please provide an assessment of the impact of the aid on the risk of customer foreclosure and possible commitments to avoid or alleviate these concerns.*

*Crowding out effects describe the economic phenomenon when public sector spending reduces or eliminates private sector spending in a particular industry. Please provide an assessment of the impact of the aid on the risk of crowding out effects (i.e., why the State aid to your company will not deter your competitors’ investments in R&D&I and FID to develop competing technologies) and possible commitments to avoid or alleviate these concerns.*

* + 1. Limiting the risk of dominance

*Dominance has been defined under Union law as a position of economic strength enjoyed by a company, which enables it to prevent effective competition being maintained on a market concerned, by affording it the power to behave to an appreciable extent independently of its competitors, its customers and ultimately of consumers.*

*Please explain why the aid to your project will not lead your company to obtain a dominant position or strengthen its dominant position on the markets concerned and possible commitments to avoid or alleviate these concerns.*

* + 1. Not creating or maintaining an inefficient market structure

*Please justify why the technology/outcome you are developing with State aid is not located in an ‘inefficient’ market suffering from for example overcapacity nor a declining sector.*

* + 1. No effect on location activities

*Describe what has influenced your choice of location of the project.*

*Please describe also if the aid to your project is conditional on the relocation of a production activity or any other activity of the company from another Contracting Party to the EEA Agreement to the territory of the Member State granting the aid.*

1. Reporting

*Please commit to report annually towards your respective Member States authorities concerning the execution of your individual project (regarding the execution of the activities, the advancements of the individual projects, the individually committed spillovers, the compliance with the principle of ‘do no significant harm’, etc.) using a reporting template.*

1. Annexes to the project portfolio
2. *Funding Gap Questionnaire / Tables*
3. *Documents demonstrating the collaborations with other participants*
4. *List of abbreviations used in the PP*
5. *Glossary of the technical terms used in the PP*
6. *Documents corroborating costs, revenues, underlying calculation assumptions, etc.*
7. *Others as appropriate (please specify)*

1. In the [2023 Microelectronics IPCEI](https://ec.europa.eu/commission/presscorner/detail/en/ip_23_3087) [Commission decision of 8 June 2023], Member States have identified associated partners/participants in an Annex to the Chapeau, which could be mentioned in the decision because they receive other kind of support under national programmes and have collaborations under the IPCEI. The Commission may, if appropriate, note the information in an Annex to the decision without, however, assessing any State aid or the respective collaborations. [↑](#footnote-ref-2)
2. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02014R0651-20210801> [↑](#footnote-ref-3)
3. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02014R0651-20210801> [↑](#footnote-ref-4)
4. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A52014XC0731%2801%29> [↑](#footnote-ref-5)
5. For instance: the European Green Deal, the Digital Strategy and the Digital Decade, the New Industrial Strategy for Europe and its update or the European Strategy for Data and Next Generation EU. [↑](#footnote-ref-6)
6. *“the capital and operating expenditures to the extent and for the period used for the project, as long as the first industrial deployment follows on from an R&D&I activity and itself contains an important R&D&I component which constitutes an integral and necessary element for the successful implementation of the project. The operating expenditures must be related to such component of the project.”* [↑](#footnote-ref-7)
7. Reference to (g) in the annex of the IPCEI Communication from the Commission (2021/C(2021) 8481 final) [↑](#footnote-ref-8)
8. <https://pages.stern.nyu.edu/~adamodar/pc/datasets/betaEurope.xls>; [pages.stern.nyu.edu/~adamodar/New\_Home\_Page/datafile/ctryprem.html](https://pages.stern.nyu.edu/~adamodar/New_Home_Page/datafile/ctryprem.html)  [↑](#footnote-ref-9)
9. The cash balance in a certain year corresponds to the cumulative sum of cashflows generated by your project up to and including that year. [↑](#footnote-ref-10)
10. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv%3AOJ.C_.2022.080.01.0001.01.ENG&toc=OJ%3AC%3A2022%3A080%3ATOC> [↑](#footnote-ref-11)
11. *This comparison is useful to distinguish from the type of activities that the company is doing as a standard business practice – e.g., if it has already established and habitually supports a wide network of collaborations with ROs, or it habitually publishes scientific papers on the research done, or it already offers sharing its research facilities with SMEs. To this end, for some spillover effects there might not be a comparison.* [↑](#footnote-ref-12)
12. Natural resources comprise energy, materials, metals, water, biomass, air and land. [↑](#footnote-ref-13)
13. For instance, inefficiencies can be minimised by significantly increasing the durability, reparability, upgradability and reusability of products or by significantly reducing resources through the design and choice of materials, facilitating repurposing, disassembly and deconstruction, in particular to reduce the use of building materials and promote the reuse of building materials. Additionally, transitioning to ‘product-as-a-service business models and circular value chains with the aim of keeping products, components and materials at their highest utility and value for as long as possible. A significant reduction in the content of hazardous substance in materials and products, including by replacing them with safer alternatives. Significantly reducing food waste in the production, processing, manufacturing or distribution of food. [↑](#footnote-ref-14)
14. Pollutant means a substance, vibration, heat, noise, light or other contaminant present in air, water or land, which may be harmful to human health or the environment. [↑](#footnote-ref-15)
15. [EUR-Lex - 02009L0125-20121204 - EN - EUR-Lex (europa.eu)](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02009L0125-20121204) [↑](#footnote-ref-16)
16. [EUR-Lex - 02011L0065-20240801 - EN - EUR-Lex (europa.eu)](https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02011L0065-20240801) [↑](#footnote-ref-17)
17. In line with Article 2(16) of the Taxonomy Regulation, “‘good condition’ means, in relation to an ecosystem, that the ecosystem is in good physical, chemical and biological condition or of a good physical, chemical and biological quality with self-reproduction or self-restoration capability, in which species composition, ecosystem structure and ecological functions are not impaired;” [↑](#footnote-ref-18)